Clinical trial
A Prospective, Multicenter, Randomized, Sham-Controlled Study Evaluating the Metabolic Effects of pulsENDO Therapy in Adults With Type 2 Diabetes (pULSENDO Study)
NCT07768631 is registered in ClinicalTrials.gov with Endogenex, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Multicenter, Randomized, Sham-Controlled Study Evaluating the Metabolic Effects of pulsENDO Therapy in Adults With Type 2 Diabetes (pULSENDO Study)
- Lead sponsor
- Endogenex, Inc.
- Phase
- Not applicable
- Overall status
- Not yet recruiting
- Start date
- January 1, 2027
- Completion date
- November 1, 2030
- Enrollment
- 320 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
diabetes, diabetes (dm), diabetes type 2, glycemic control, glycemic control for diabetes mellitus, weight change